Jan van Heek
Director/Board Member bij MINERVA NEUROSCIENCES, INC.
Vermogen: 6 558 $ op 31-03-2024
Profiel
Jan G.
van Heek is the founder of Bio Point Group LLC, which was founded in 2009, where he holds the title of Partner & Principal.
Currently, he is an Independent Director at Minerva Neurosciences, Inc. since 2014.
Mr. van Heek's former positions include Chairman at BioVex, Inc. from 2007 to 2009, Director at ViaCell, Inc. from 2002 to 2007, and Executive Vice President at Genzyme Corp.
and Genzyme Ltd.
He also served as a Member-Supervisory Board at to-BBB Holding BV and Director-Supervisory Board at PanGenetics BV and to-BBB technologies BV.
Mr. van Heek's education includes an undergraduate degree from Stanford University and an MBA from the University of St. Gallen.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-09-2023 | 2 542 ( 0.04% ) | 6 558 $ | 31-03-2024 |
Actieve functies van Jan van Heek
| Bedrijven | Functie | Begin |
|---|---|---|
| MINERVA NEUROSCIENCES, INC. | Director/Board Member | 01-07-2014 |
| Bio Point Group LLC | Founder | 01-01-2009 |
Eerdere bekende functies van Jan van Heek
| Bedrijven | Functie | Einde |
|---|---|---|
| AMARIN CORPORATION PLC | Director/Board Member | 06-03-2023 |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Chairman | 24-01-2013 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Chairman | 01-01-2009 |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Director/Board Member | - |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Director/Board Member | 16-11-2007 |
Opleiding van Jan van Heek
| Stanford University | Undergraduate Degree |
| University of St. Gallen | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AMARIN CORPORATION PLC | Health Technology |
| MINERVA NEUROSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 11 |
|---|---|
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Genzyme Ltd
 Genzyme Ltd Medical SpecialtiesHealth Technology Part of Sanofi, Genzyme Ltd is a private company that specializes in biological healthcare products. The company is based in Cambridge, MA. | Health Technology |
PanGenetics BV
 PanGenetics BV Miscellaneous Commercial ServicesCommercial Services PanGenetics BV researches and develops antibody-based therapeutic products. It specializes in taking antibodies at the late research stage through to clinical proof of concept. The firm’s advanced programs are PG102, a CD40 antagonist, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company was founded by Mark de Boer and James W. Larrick in 1995 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
to-BBB Holding BV
 to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Health Technology |
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
| Bio Point Group LLC |
